Yaw Sarpong Bediako

Diagnostic Herbal Industry
Ghana

Abstract Title:

QUALITY HERBAL MEDICINES THE FIRST CHOICE ALTERNATIVE PRACTICE FOR HEALTHCARE

Biography:

Yaw Sarpong Bediakop is a senior research phytochemist at the Diagnostic Herbal Industry (DHI), where she leads product development and quality control of herbal distillates and herbal teas. he holds an MSc in Pharmacognosy from the University of Ghana and has o ver four years of experience in standardizing traditional plant medicines. H is research interests include bioactive compound profiling, sustainable extraction methods, and clinical validation of alternative therapies. He has presented at multiple conferences on integrative healthcare and is a contributing author to the Journal of Herbal Medicine.

Research Interests:

The global shift toward alternative healthcare practices has intensified the need for standardized, high-quality herbal medicines. This paper presents Thorntina -74, a novel herbal distillate formulated from a synergistic blend of three medicinal plants —Moringa oleifera, Spondias mombin, and Tetrapleura tetraptera —as a primary candidate for first -line alternative therapy. Certified by the Food and Drugs Authority (FDA) of Ghana, Thorntina -74 contains a diverse profile of bioactive compounds including alkaloids, flavonoids, and terpenes. The purpose of this study was to evaluate its therapeutic potential using gas chromatography -mass spectrometry (GC -MS) for chemical characterization, in vitro assays for anti -inflammatory and antimicrobial activity, and in viv o analysis conducted on human subjects. Key findings revealed consistent compound profiles across three independent batches, with significant inhibition of pro -inflammatory cytokines (IL -6 and TNF-?) and broad-spectrum activity against Staphylococcus aureu s and Candida albicans. Furthermore, the human in vivo analysis demonstrated that Thorntina -74 aids in managing blood -related diseases such as anemia and coagulation disorders, while also protecting vital human organs including the liver and kidneys from oxidative damage. These results indicate that Thorntina -74 offers a reproducible, plant -based alternative for managing common infections, inflammatory conditions, hematological imbalances, and organ toxicity. The implications for alternative health practice are substantial: a standardized, FDA-approved distillate derived from indigenous plants can bridge the gap between traditional herbal knowledge and evidence -based integrative medicine, promoting patient trust and regulatory acceptance. This work supports the conference theme by demonstrating how quality -controlled herbal products can serve as safe, effective first choices in primary healthcare.